Fig. 7: Transcriptional signals from persistent prostate cancer cells can be used to stratify untreated patients.

a Heatmap of gene set variation analysis (GSVA) enrichment scores for all single-cell (sc)-derived gene signatures in the TCGA-PRAD cohort, including the marker gene sets for each scRNA-seq cluster. Hierarchical clustering of the GSVA scores was used to separate the samples into two groups, labeled Branch 1 and Branch 2. b Kaplan–Meier survival curve for TCGA–PRAD patients stratified into two groups as indicated in panel a. The two-sided log-rank p-value is shown within the plot. c–h Kaplan–Meier survival curves for TCGA–PRAD patients stratified into two groups based on median GSVA score for ENZ-induced cluster, PROSGenesis, Persist, persistent cluster, AR activity, and ARFL gene signatures. In each plot, the two-sided log-rank p-value is indicated above the plotted curves. i Summary table of gene signature GSVA score associations with progression-free survival (PFS) in the TCGA–PRAD and ICGC–EOPC datasets. Only gene signatures significantly associated with PFS in one or both datasets are shown. Good indicates that a higher score for the signature (a score higher than the median) is associated with better survival outcome, while poor indicates that a higher signature score is associated with worse survival outcome. Two-sided log-rank p-values are shown in parentheses. For each dataset, the header indicates the number of samples included. ENZ = enzalutamide, NEPC = neuroendocrine prostate cancer. See also Supplementary Fig. 7.